Back to mobile site

Piper Sandler on Kymera Therapeutics (KYMR): 'All Eyes on BroADen2 Data in 4Q'

September 23, 2026 8:41 AM EDT Send to a Friend
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $140.00 price target on Kymera Therapeutics (NASDAQ: KYMR).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login